A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD

Margaret Weiss, Rosemary Tannock, Christopher J Kratochvil, David Dunn, Jesus Velez-Borras, Christine Thomason, Roy Tamura, Douglas Kelsey, Linda Stevens, Albert J. Allen

Research output: Contribution to journalArticle

111 Citations (Scopus)

Abstract

Objective: Five studies have demonstrated the effectiveness of atomoxetine compared with placebo in reducing symptoms of attention-deficit/hyperactivity disorder (ADHD) based on parent reports. The primary objective of this clinical trial was to assess the efficacy of once-daily atomoxetine compared with placebo using teacher reports. Method: One hundred fifty-three patients aged 8-12 years were randomly assigned to receive once-daily atomoxetine or placebo in a 2:1 ratio for 7 weeks. ADHD symptoms at school were primarily assessed by baseline-to-endpoint change on the Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Teacher Version: Investigator administered and scored (ADHDRS-IV-Teacher:Inv) as rated by investigators using teacher reports. Results: ADHDRS-IV-Teacher:Inv total scores were significantly lower for children treated with atomoxetine compared with those treated with placebo (p = .001 ). Similar results were observed for the inattentive (p = .016) and hyperactive/impulsive (p < .001) ADHDRS-IV-Teacher:Inv subscales, the clinician-rated Clinical Global Impressions severity scale (p = .001), the Conners Global Index-Teacher scale (p = .008), and the Conners Parent Rating Scale-Revised: Short Form ADHD Index T-Score (p < .001). Discontinuations due to adverse events were low in both groups (atomoxetine 5.9%, placebo 0%, p = .096). Conclusions: This study extends previous results based on parent reports showing that once-daily administration of atomoxetine is safe and effective in improving ADHD symptoms in children and demonstrates that outcomes at school are similar when symptoms are reported by teachers.

Original languageEnglish (US)
Pages (from-to)647-655
Number of pages9
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume44
Issue number7
DOIs
StatePublished - Jan 1 2005

Fingerprint

Attention Deficit Disorder with Hyperactivity
Placebos
Research Personnel
Atomoxetine Hydrochloride
Clinical Trials

Keywords

  • Atomoxetine
  • Attention-deficit/hyperactivity disorder
  • Nonstimulants
  • School

ASJC Scopus subject areas

  • Developmental and Educational Psychology
  • Psychiatry and Mental health

Cite this

A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. / Weiss, Margaret; Tannock, Rosemary; Kratochvil, Christopher J; Dunn, David; Velez-Borras, Jesus; Thomason, Christine; Tamura, Roy; Kelsey, Douglas; Stevens, Linda; Allen, Albert J.

In: Journal of the American Academy of Child and Adolescent Psychiatry, Vol. 44, No. 7, 01.01.2005, p. 647-655.

Research output: Contribution to journalArticle

Weiss, Margaret ; Tannock, Rosemary ; Kratochvil, Christopher J ; Dunn, David ; Velez-Borras, Jesus ; Thomason, Christine ; Tamura, Roy ; Kelsey, Douglas ; Stevens, Linda ; Allen, Albert J. / A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. In: Journal of the American Academy of Child and Adolescent Psychiatry. 2005 ; Vol. 44, No. 7. pp. 647-655.
@article{4684786f692645248a6ac31446f0a1c1,
title = "A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD",
abstract = "Objective: Five studies have demonstrated the effectiveness of atomoxetine compared with placebo in reducing symptoms of attention-deficit/hyperactivity disorder (ADHD) based on parent reports. The primary objective of this clinical trial was to assess the efficacy of once-daily atomoxetine compared with placebo using teacher reports. Method: One hundred fifty-three patients aged 8-12 years were randomly assigned to receive once-daily atomoxetine or placebo in a 2:1 ratio for 7 weeks. ADHD symptoms at school were primarily assessed by baseline-to-endpoint change on the Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Teacher Version: Investigator administered and scored (ADHDRS-IV-Teacher:Inv) as rated by investigators using teacher reports. Results: ADHDRS-IV-Teacher:Inv total scores were significantly lower for children treated with atomoxetine compared with those treated with placebo (p = .001 ). Similar results were observed for the inattentive (p = .016) and hyperactive/impulsive (p < .001) ADHDRS-IV-Teacher:Inv subscales, the clinician-rated Clinical Global Impressions severity scale (p = .001), the Conners Global Index-Teacher scale (p = .008), and the Conners Parent Rating Scale-Revised: Short Form ADHD Index T-Score (p < .001). Discontinuations due to adverse events were low in both groups (atomoxetine 5.9{\%}, placebo 0{\%}, p = .096). Conclusions: This study extends previous results based on parent reports showing that once-daily administration of atomoxetine is safe and effective in improving ADHD symptoms in children and demonstrates that outcomes at school are similar when symptoms are reported by teachers.",
keywords = "Atomoxetine, Attention-deficit/hyperactivity disorder, Nonstimulants, School",
author = "Margaret Weiss and Rosemary Tannock and Kratochvil, {Christopher J} and David Dunn and Jesus Velez-Borras and Christine Thomason and Roy Tamura and Douglas Kelsey and Linda Stevens and Allen, {Albert J.}",
year = "2005",
month = "1",
day = "1",
doi = "10.1097/01.chi.0000163280.47221.c9",
language = "English (US)",
volume = "44",
pages = "647--655",
journal = "Journal of the American Academy of Child and Adolescent Psychiatry",
issn = "0890-8567",
publisher = "Elsevier Limited",
number = "7",

}

TY - JOUR

T1 - A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD

AU - Weiss, Margaret

AU - Tannock, Rosemary

AU - Kratochvil, Christopher J

AU - Dunn, David

AU - Velez-Borras, Jesus

AU - Thomason, Christine

AU - Tamura, Roy

AU - Kelsey, Douglas

AU - Stevens, Linda

AU - Allen, Albert J.

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Objective: Five studies have demonstrated the effectiveness of atomoxetine compared with placebo in reducing symptoms of attention-deficit/hyperactivity disorder (ADHD) based on parent reports. The primary objective of this clinical trial was to assess the efficacy of once-daily atomoxetine compared with placebo using teacher reports. Method: One hundred fifty-three patients aged 8-12 years were randomly assigned to receive once-daily atomoxetine or placebo in a 2:1 ratio for 7 weeks. ADHD symptoms at school were primarily assessed by baseline-to-endpoint change on the Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Teacher Version: Investigator administered and scored (ADHDRS-IV-Teacher:Inv) as rated by investigators using teacher reports. Results: ADHDRS-IV-Teacher:Inv total scores were significantly lower for children treated with atomoxetine compared with those treated with placebo (p = .001 ). Similar results were observed for the inattentive (p = .016) and hyperactive/impulsive (p < .001) ADHDRS-IV-Teacher:Inv subscales, the clinician-rated Clinical Global Impressions severity scale (p = .001), the Conners Global Index-Teacher scale (p = .008), and the Conners Parent Rating Scale-Revised: Short Form ADHD Index T-Score (p < .001). Discontinuations due to adverse events were low in both groups (atomoxetine 5.9%, placebo 0%, p = .096). Conclusions: This study extends previous results based on parent reports showing that once-daily administration of atomoxetine is safe and effective in improving ADHD symptoms in children and demonstrates that outcomes at school are similar when symptoms are reported by teachers.

AB - Objective: Five studies have demonstrated the effectiveness of atomoxetine compared with placebo in reducing symptoms of attention-deficit/hyperactivity disorder (ADHD) based on parent reports. The primary objective of this clinical trial was to assess the efficacy of once-daily atomoxetine compared with placebo using teacher reports. Method: One hundred fifty-three patients aged 8-12 years were randomly assigned to receive once-daily atomoxetine or placebo in a 2:1 ratio for 7 weeks. ADHD symptoms at school were primarily assessed by baseline-to-endpoint change on the Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Teacher Version: Investigator administered and scored (ADHDRS-IV-Teacher:Inv) as rated by investigators using teacher reports. Results: ADHDRS-IV-Teacher:Inv total scores were significantly lower for children treated with atomoxetine compared with those treated with placebo (p = .001 ). Similar results were observed for the inattentive (p = .016) and hyperactive/impulsive (p < .001) ADHDRS-IV-Teacher:Inv subscales, the clinician-rated Clinical Global Impressions severity scale (p = .001), the Conners Global Index-Teacher scale (p = .008), and the Conners Parent Rating Scale-Revised: Short Form ADHD Index T-Score (p < .001). Discontinuations due to adverse events were low in both groups (atomoxetine 5.9%, placebo 0%, p = .096). Conclusions: This study extends previous results based on parent reports showing that once-daily administration of atomoxetine is safe and effective in improving ADHD symptoms in children and demonstrates that outcomes at school are similar when symptoms are reported by teachers.

KW - Atomoxetine

KW - Attention-deficit/hyperactivity disorder

KW - Nonstimulants

KW - School

UR - http://www.scopus.com/inward/record.url?scp=21044444747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21044444747&partnerID=8YFLogxK

U2 - 10.1097/01.chi.0000163280.47221.c9

DO - 10.1097/01.chi.0000163280.47221.c9

M3 - Article

VL - 44

SP - 647

EP - 655

JO - Journal of the American Academy of Child and Adolescent Psychiatry

JF - Journal of the American Academy of Child and Adolescent Psychiatry

SN - 0890-8567

IS - 7

ER -